BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7532717)

  • 1. A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus.
    Stafford FJ; Fleisher TA; Lee G; Brown M; Strand V; Austin HA; Balow JE; Klippel JH
    J Rheumatol; 1994 Nov; 21(11):2068-70. PubMed ID: 7532717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function.
    Fishwild DM; Strand V
    J Rheumatol; 1994 Apr; 21(4):596-604. PubMed ID: 7518519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate.
    Cannon GW; Marble DA; Griffiths MM; Cole BC; McCall S; Schulman SF; Strand V
    J Rheumatol; 1995 Feb; 22(2):207-13. PubMed ID: 7537827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
    Fishwild DM; Aberle S; Bernhard SL; Kung AH
    Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
    Wouters CH; Diegenant C; Ceuppens JL; Degreef H; Stevens EA
    Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
    Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
    Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
    Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team.
    Skyler JS; Lorenz TJ; Schwartz S; Eisenbarth GS; Einhorn D; Palmer JP; Marks JB; Greenbaum C; Saria EA; Byers V
    J Diabetes Complications; 1993; 7(4):224-32. PubMed ID: 7693056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotoxin depletion of T cells and its effect on hematopoietic progenitor cells in human cord blood.
    Xu M; Lu S; Shen B; Li Y
    Chin Med J (Engl); 2001 Apr; 114(4):355-9. PubMed ID: 11780453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group.
    Strand V; Lipsky PE; Cannon GW; Calabrese LH; Wiesenhutter C; Cohen SB; Olsen NJ; Lee ML; Lorenz TJ; Nelson B
    Arthritis Rheum; 1993 May; 36(5):620-30. PubMed ID: 7683881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.
    Huang W; Sinha J; Newman J; Reddy B; Budhai L; Furie R; Vaishnaw A; Davidson A
    Arthritis Rheum; 2002 Jun; 46(6):1554-62. PubMed ID: 12115186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y; Horiuchi T; Tsukamoto H; Otsuka J; Mitoma H; Kimoto Y; Nakashima H; Muta K; Abe Y; Kiyohara C; Ueda A; Nagasawa K; Yoshizawa S; Shimoda T; Harada M
    Rheumatology (Oxford); 2008 Jun; 47(6):821-7. PubMed ID: 18397955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.